Premier Alternatives

Naveris

Waltham, MA · Founded 2017 · Privately Held (backing)

Developer of a blood test technology designed to detect specific cancer subtypes and improve patient outcomes. Naveris is based in Waltham, MA and was founded in 2017. Its last known valuation is $81.5 million. It has raised $85.5 million across 3 recorded rounds; the latest was a $17.5 million early-stage round in Jun 2024.

Last price · $/share
—
Implied valuation
$81.5M
Total raised
$85.5M
Last round
Early Stage VC
Jun 2024

Naveris key facts

  • Developer of a blood test technology designed to detect specific cancer subtypes and improve patient outcomes.
  • Naveris’s last known valuation is $81.5M.
  • It has raised $85.5M across 3 recorded rounds; the latest was Early Stage VC ($17.5M) in Jun 2024.
  • Notable investors include Ms2 Capital, BrightEdge, ABI LAB, American Cancer Society, B-FLEXION Life Sciences — 7 tracked in total.
  • Naveris has filed 3 Form Ds with the SEC since 2019, most recently Jul 2024 ($17.5M sold to 5 investors).
  • Status: Privately Held (backing).
Free account
More of Naveris with a free account
  • ·Watch Naveris: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Naveris funding rounds

3 rounds
Jun 2024Early Stage VC$17.5MSEC filing▮
Feb 2020Early Stage VC$15.4MSEC filing▮
Sep 2019Seed Round$650KSEC filing▮
Full funding history →

Naveris valuation

Naveris's last known valuation is $81.5 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Naveris raised?

Naveris has raised $85.5 million in total; 3 of its rounds are on record, from 2019 on. The largest on record was a $650,000 seed round in Sep 2019; the most recent was a $17.5 million early-stage round in Jun 2024.

Naveris has filed 3 Form Ds with the SEC since 2019, most recently in Jul 2024 ($17.5 million sold to 5 investors).

Naveris investors

7 investors are on record for Naveris, including Ms2 Capital, BrightEdge, ABI LAB and American Cancer Society. The early-stage round in Jun 2024 drew 5 investors.

About Naveris

Developer of a blood test technology designed to detect specific cancer subtypes and improve patient outcomes. The company's biomimetic technology replicates the morphological, signaling, and cell lineage complexity of human tissues and tumors ex vivo, enabling patients to get an early diagnosis with real-time monitoring of response and detection of cancer recurrence.

Sector
Healthcare
HQ
Waltham, MA, United States
Founded
2017
Employees
53
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$81.5M

Naveris’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.